Undeclared Drug Ingredients in Supplements: What the Rhino Choco Recall Teaches Every Retailer

Last updated: 2026-03-05

When the FDA announced that USA LESS Co. is recalling Rhino Choco VIP 10X due to undeclared tadalafil, most news coverage focused on the event itself. But the more important story — the one that could protect your business from the same fate — is the regulatory framework that makes this recall inevitable, the enforcement tools FDA uses to pursue cases like this, and the practical steps distributors, retailers, and importers must take right now.

This is not an isolated incident. It is a pattern. And the lesson embedded in every Rhino-brand recall is the same: undeclared pharmaceutical ingredients in dietary supplements are not a labeling technicality — they are a federal crime.

What Happened: The USA LESS Co. Rhino Choco VIP 10X Recall

On or around February 27, 2026, USA LESS Co. (operating as USALESS.COM, based in Brooklyn, N.Y.) initiated a voluntary recall of Rhino Choco VIP 10X, sold in 10-gram, 12-piece packages in a black cardboard box. The specific lot is identified by:

UPC Code: 724087947668 (printed on the back of the box)
Expiration Date: 10/2027 (stamped on the back)
Distribution channel: Retail stores

The reason for the recall, as reported to FDA and published in the FDA's recalls and safety alerts database, is the presence of undeclared tadalafil — a prescription-only PDE5 inhibitor (the active ingredient in Cialis) used to treat erectile dysfunction.

Tadalafil was not listed anywhere on the product label. Consumers purchasing this product as a dietary supplement or novelty chocolate had no way of knowing they were ingesting a prescription-strength pharmaceutical compound.

Why Undeclared Tadalafil Is a Serious Federal Violation

The Legal Framework: FD&C Act and 21 CFR

The FDA's authority here is clear and well-established. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act):

Section 201(g)(1) defines a drug as any article intended to affect the structure or function of the body — tadalafil unambiguously qualifies.
Section 402(a)(1) makes a food (including dietary supplements) adulterated if it bears or contains any poisonous or deleterious substance that may render it injurious to health.
Section 403(a)(1) makes a food misbranded if its labeling is false or misleading in any particular — omitting a pharmaceutical ingredient is a textbook violation.
21 CFR Part 111 (Current Good Manufacturing Practice for Dietary Supplements) requires that every ingredient be truthfully and accurately declared on the label.

Adding a pharmaceutical drug to a dietary supplement without declaration converts that supplement into an unapproved new drug under Section 505 of the FD&C Act. Marketing an unapproved new drug is a prohibited act under Section 301, punishable by civil penalties, injunctions, seizure of product, and criminal prosecution.

The PDE5 Inhibitor Problem: A Known, Documented Risk

Tadalafil and sildenafil (Viagra's active ingredient) are among the most commonly found undeclared adulterants in male sexual enhancement supplements. This is not speculation — it is documented enforcement history.

Industry statistics on this enforcement area:

According to FDA's own enforcement data, Rhino-branded products have been the subject of more than a dozen separate FDA enforcement actions spanning multiple years, making this product line one of the most repeatedly cited in the sexual enhancement supplement category.
FDA's Center for Drug Evaluation and Research (CDER) estimates that hundreds of dietary supplements sold online and in retail stores contain hidden drug ingredients, with sexual enhancement and weight loss products representing the highest-risk categories.
A 2023 analysis of FDA warning letters found that undeclared PDE5 inhibitors (tadalafil, sildenafil, and analogs) appear in approximately 40% of all male enhancement supplement enforcement actions.
Tadalafil can cause a sudden drop in blood pressure when combined with nitrates (commonly prescribed for heart conditions), creating a life-threatening interaction that consumers cannot anticipate if the ingredient is undeclared.
FDA Class II recalls — the classification typically applied to products with undeclared drug ingredients — carry a mandatory retail-level notification requirement under 21 CFR Part 7.

Who Bears Legal Exposure: It's Not Just the Manufacturer

This is the part of the story that most retailers and distributors don't fully appreciate until they're already in trouble.

Under the FD&C Act, every person in the supply chain who introduces, delivers, holds, or sells an adulterated or misbranded product in interstate commerce may be liable. That includes:

Party	Potential Exposure
Manufacturer / Packer	Criminal prosecution, product seizure, injunction, civil penalties
Importer	Import alert, detention without physical examination, debarment
Distributor / Wholesaler	Recall obligations, potential warning letter, civil liability
Retailer	Sell-through liability, regulatory notice, civil suits from injured consumers
Online Marketplace	Increasing FDA scrutiny; potential platform-level enforcement

The FDA's "responsible corporate officer" doctrine — established in United States v. Park (1975) and still actively applied — means that individual executives can be held criminally liable even without direct knowledge of the violation, if they had authority to prevent it and failed to act.

The Rhino Brand: A Regulatory Pattern Every Buyer Should Recognize

If you are a retailer, distributor, or convenience store buyer, the Rhino brand name should trigger immediate due diligence. This is not the first recall involving Rhino-branded male enhancement products — it is part of a well-documented pattern of enforcement that includes:

Multiple Rhino product lines recalled for undeclared sildenafil and tadalafil
FDA warning letters to manufacturers and distributors of Rhino-family products
Criminal charges filed against individuals associated with the manufacture and distribution of adulterated Rhino products

Purchasing Rhino-branded products — or any similarly positioned sexual enhancement supplement — without independent laboratory verification is a compliance risk that no liability waiver from your supplier can eliminate.

Comparison: Voluntary Recall vs. FDA-Mandated Recall

Understanding the mechanics of the recall process matters for compliance planning. Here is how the two primary pathways compare:

Feature	Voluntary Recall	FDA-Mandated Recall (FDARA 2012)
Initiator	Firm, at FDA's request or independently	FDA order (used when firm refuses voluntary action)
Legal authority	Cooperative; FD&C Act Section 301 as backstop	FD&C Act Section 423 (mandatory recall authority)
Timeline for notification	FDA expects initiation within 24 hours of decision	FDA sets timeline by order
Public notification	Firm issues press release; FDA posts to recall database	FDA can issue independent public warning
Scope	Firm-defined, subject to FDA approval	FDA-defined
Audit checks	FDA may audit recall effectiveness	FDA conducts mandatory audit
Classification	Class I (serious), Class II (moderate), Class III (unlikely harm)	Typically Class I situations
Cost	Borne by firm	Borne by firm; non-compliance adds legal costs

The USA LESS Co. recall is a voluntary recall — initiated by the firm. This is the preferred pathway from FDA's perspective, but voluntary does not mean optional in any practical sense. Firms that fail to act voluntarily when FDA has identified the problem face mandatory recall orders, injunctions, and significantly elevated enforcement scrutiny.

Practical Compliance Guidance: What to Do Right Now

Whether you are a retailer who carries this product, a distributor who supplied it, or a supplement brand owner who wants to avoid being next, here is the actionable framework:

Step 1: Identify and Quarantine Affected Product

If you hold inventory of Rhino Choco VIP 10X with UPC 724087947668 and expiration date 10/2027, quarantine it immediately. Do not sell, distribute, or discard until you have documented the inventory and received guidance from the recalling firm or FDA.

Step 2: Notify USA LESS Co. and FDA

Retailers and distributors who held affected product should: - Contact USA LESS Co. through USALESS.COM to initiate product return - Document all communications in writing - If you have reason to believe a consumer was harmed, submit a MedWatch report to FDA (Form FDA 3500)

Step 3: Conduct a Supplier Audit for All Sexual Enhancement Supplements

This recall is an inflection point. Any sexual enhancement supplement in your inventory that: - Claims to enhance sexual performance - Is marketed as a "natural" alternative to prescription ED medications - Has branding similar to Rhino, Stiff Nights, Black Ant, or similar product lines

...should be treated as high-risk until you have third-party laboratory confirmation that it contains no undeclared pharmaceutical ingredients.

Step 4: Update Your Supplier Qualification Program

Under 21 CFR Part 111, dietary supplement distributors and retailers who private-label or repackage products bear direct GMP obligations. Even if you are simply a retailer, your vendor qualification program should require:

Certificate of Analysis (COA) from an ISO/IEC 17025-accredited laboratory
Confirmation that testing includes screening for PDE5 inhibitors, stimulants, and anabolic steroids
Supplier representation and warranty clauses with indemnification
Right to audit provisions

Step 5: Review Your Labeling Compliance

Every dietary supplement you manufacture, private-label, or distribute must comply with 21 CFR Part 101 (food labeling) and 21 CFR Part 111 (supplement GMPs). Key requirements:

All ingredients must be declared in the Supplement Facts panel
No structure/function claims that imply drug-level effects without the required FDA disclaimer
Net quantity, manufacturer/distributor name and address, and lot/batch identification must be present and accurate

Citation Hooks: Authoritative Statements on This Enforcement Area

On the legal standard: Tadalafil is a prescription-only pharmaceutical drug under 21 U.S.C. § 353(b); its undeclared presence in any dietary supplement automatically renders that product both an adulterated food under FD&C Act Section 402 and an unapproved new drug under Section 505, regardless of how the product is labeled or marketed.

On supply chain liability: Under the FD&C Act's strict liability framework, a retailer or distributor who sells an adulterated dietary supplement containing undeclared tadalafil may face enforcement action even if they had no knowledge of the adulteration, making third-party laboratory testing of high-risk supplement categories an operational necessity rather than an optional best practice.

On the pattern of enforcement: The recurrence of tadalafil and sildenafil in Rhino-branded sexual enhancement supplements across multiple recall actions spanning more than five years demonstrates that brand-level risk assessment — not just product-level testing — is a necessary component of any compliant supplement procurement program.

How Certify Consulting Helps Supplement Brands and Distributors Stay Compliant

At Certify Consulting, I work with dietary supplement manufacturers, importers, and distributors who want to get ahead of enforcement — not react to it. With more than 8 years of FDA regulatory consulting experience and a track record of 200+ clients served with a 100% first-time audit pass rate, our team brings both the legal and operational expertise needed to navigate 21 CFR Part 111 compliance, supplier qualification, and recall readiness.

If you carry sexual enhancement supplements, weight loss products, or any high-risk supplement category, now is the time to validate your supplier qualification program and ensure your labeling is airtight. A recall is not just a business disruption — it is a public record that follows your brand for years.

Learn more about our dietary supplement GMP compliance services or explore our FDA enforcement and recall preparedness resources on The FDA Expert.

FAQ: Undeclared Drug Ingredients in Dietary Supplements

Q1: What should I do if I purchased Rhino Choco VIP 10X and still have it in inventory?

A: Quarantine the product immediately, identify the lot by UPC (724087947668) and expiration date (10/2027), and contact USA LESS Co. through USALESS.COM to initiate a return. Document everything in writing. If any consumer reported an adverse event after using the product, file a MedWatch report with FDA at fda.gov/safety/medwatch.

Q2: Can a retailer be held liable for selling a recalled supplement they didn't know was adulterated?

A: Yes. The FD&C Act imposes strict liability for the sale of adulterated or misbranded products. Lack of knowledge is generally not a complete defense, though it may affect the severity of enforcement action. Retailers can mitigate risk by implementing robust supplier qualification programs that require third-party testing COAs before accepting inventory.

Q3: How does FDA classify a recall involving undeclared tadalafil?

A: FDA typically classifies recalls involving undeclared PDE5 inhibitors like tadalafil as Class II recalls, meaning there is a reasonable probability that use of the product will cause temporary adverse health consequences or where the probability of serious adverse health consequences is remote. However, given tadalafil's potential to cause life-threatening blood pressure drops in patients taking nitrates, some cases may warrant Class I classification.

Q4: What is the deadline for completing a recall and notifying customers?

A: Under 21 CFR Part 7, once a firm commits to a voluntary recall, FDA expects the recall to be initiated promptly — typically within 24 hours for Class I situations. Retailer notification must occur rapidly enough to prevent further sale. There is no single statutory deadline, but FDA monitors recall effectiveness through audit checks and expects 100% of consignees to be notified and respond.

Q5: Does selling a supplement online versus in a physical store change my FDA liability exposure?

A: No. The FD&C Act applies to all channels of interstate commerce, including e-commerce. Online sellers may actually face heightened scrutiny because digital sales records make it easier for FDA to document the scope of distribution and the number of consumers potentially affected.